Biocartis NV logo

BCART - Biocartis NV Share Price

€4.41 -0.2  -3.5%

Last Trade - 26/02/21

Sector
Healthcare
Size
Small Cap
Market Cap £219.9m
Enterprise Value £243.2m
Revenue £37.4m
Position in Universe 415th / 846
Bullish
Bearish
Unlock BCART Revenue
Momentum
Relative Strength (%)
1m -4.76%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -25.5%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
13.3 12.1 21.0 27.8 37.4 43.1 62.6 86.5 +26.5%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020,Biocartis Group NV revenues increased 15% to EUR43.1M. Netloss decreased 2% to EUR62.9M. Revenues reflect ProductSales Revenue increase of 32% to EUR31.9M, Service revenueincrease of 62% to EUR1.2M. Lower net loss reflects Grantsand Other Income increase from EUR288K to EUR12.4M (income), Share in the results of associates decrease of 16% toEUR532K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

BCART Revenue Unlock BCART Revenue

Net Income

BCART Net Income Unlock BCART Revenue

Normalised EPS

BCART Normalised EPS Unlock BCART Revenue

PE Ratio Range

BCART PE Ratio Range Unlock BCART Revenue

Dividend Yield Range

BCART Dividend Yield Range Unlock BCART Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
BCART EPS Forecasts Unlock BCART Revenue
Profile Summary

Biocartis Group NV is a Belgium-based company, which specializes in the development of molecular diagnostic systems, especially for the treatment of cancers and infectious diseases, the products ensure the analysis of biomolecules associated with risk factors, early detection, treatment selection and monitoring of disease. The group has the Idylla system to deliver results within a period of between 35 to 150 minutes.

Directors
Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated November 24, 2014
Public Since April 27, 2015
No. of Shareholders: n/a
No. of Employees: 462
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index
Exchange Euronext - Brussels
Shares in Issue 57,545,663
Free Float (0.0%)
Eligible for
ISAs
SIPPs
BCART Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for BCART
Upcoming Events for BCART
Frequently Asked Questions for Biocartis NV
What is the Biocartis NV share price?

As of 26/02/21, shares in Biocartis NV are trading at €4.41, giving the company a market capitalisation of £219.9m. This share price information is delayed by 15 minutes.

How has the Biocartis NV share price performed this year?

Shares in Biocartis NV are currently trading at €4.41 and the price has moved by -14.37% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Biocartis NV price has moved by -20.9% over the past year.

What are the analyst and broker recommendations for Biocartis NV?

Of the analysts with advisory recommendations for Biocartis NV, there are there are currently 2 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Biocartis NV is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Biocartis NV next release its financial results?

Biocartis NV is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Biocartis NV dividend yield?

Biocartis NV does not currently pay a dividend.

Does Biocartis NV pay a dividend?

Biocartis NV does not currently pay a dividend.

When does Biocartis NV next pay dividends?

Biocartis NV does not currently pay a dividend.

How do I buy Biocartis NV shares?

To buy shares in Biocartis NV you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Biocartis NV?

Shares in Biocartis NV are currently trading at €4.41, giving the company a market capitalisation of £219.9m.

Where are Biocartis NV shares listed? Where are Biocartis NV shares listed?

Here are the trading details for Biocartis NV:

Country of listing: Belgium
Exchange: BRU
Ticker Symbol: BCART
What kind of share is Biocartis NV?

Based on an overall assessment of its quality, value and momentum, Biocartis NV is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Biocartis NV share price forecast 2021?

Shares in Biocartis NV are currently priced at €4.41. At that level they are trading at 63.27% discount to the analyst consensus target price of 0.00.

Analysts covering Biocartis NV currently have a consensus Earnings Per Share (EPS) forecast of -1.025 for the next financial year.

How can I tell whether the Biocartis NV share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biocartis NV. Over the past six months, the relative strength of its shares against the market has been -14.35%. At the current price of €4.41, shares in Biocartis NV are trading at -5.56% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Biocartis NV PE Ratio?

We were not able to find PE ratio data for Biocartis NV.

Who are the key directors of Biocartis NV?

Biocartis NV's management team is headed by:

Christian Reinaudo - CHM
Herman Verrelst - CEO
Luc Gijsens - NID
Leo Steenbergen - NID
Ann-Christine Sundell - NID
Harry Glorikian - NID
Roald Borre - NED
Benoit Devogelaere - CTO
Piet Houwen - COO
Who are the major shareholders of Biocartis NV?

Here are the top five shareholders of Biocartis NV based on the size of their shareholding:

Invesco Advisers, Inc. Investment Advisor
Percentage owned: 12.11% (6.97m shares)
Invesco Global Opportunities Fund Mutual Fund
Percentage owned: 10.43% (6.00m shares)
Johnson & Johnson Corporation
Percentage owned: 9.52% (5.48m shares)
Government of Flanders Government Agency
Percentage owned: 3.94% (2.27m shares)
Credit Suisse Asset Management Investment Advisor/Hedge Fund
Percentage owned: 3.53% (2.03m shares)
Similar to BCART
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.